VSL#3 can prevent ulcerative colitis-associated carcinogenesis in mice. - GreenMedInfo Summary
VSL#3 can prevent ulcerative colitis-associated carcinogenesis in mice.
World J Gastroenterol. 2018 Oct 7 ;24(37):4254-4262. PMID: 30310258
Chun-Sai-Er Wang
AIM: To investigate the effects of VSL#3 on tumor formation, and fecal and intestinal mucosal microbiota in azoxymethane/dextran sulfate sodium (AOM/DSS) induced mice model.
METHODS: C57BL/6 mice were administered AOM/DSS to develop the ulcerative colitis (UC) carcinogenesis model. Mice were treated with 5-ASA (75 mg/kg/d), VSL#3 (1.5× 10CFU/d), or 5-ASA combined with VSL#3 by gavage from the day of AOM injection for three months (five days/week). The tumor load was compared in each group, and tumor necrosis factor (TNF-α) and interleukin (IL)-6 levels were evaluated in colon tissue. The stool and intestinal mucosa samples were collected to analyze the differences in the intestinal microbiota by 16s rDNA sequencing method.
RESULTS: VSL#3 significantly reduced the tumor load in AOM/DSS-induced mice model and decreased the level of TNF-α and IL-6 in colon tissue. The model group had a lower level ofand higher level ofandin fecal microbiota than the control group. After the intervention with 5-ASA and VSL#3,andwere increased, whileandwere reduced. 5-ASA combined with VSL#3 increased theand decreased the. The intestinal mucosal microbiota analysis showed a lower level ofand_UCG-014 and higher level ofin the model group as compared to the control group. After supplementation with VSL#3,was increased. 5-ASA combined with VSL#3 increased the level of bothand.
CONCLUSION: VSL#3 can prevent UC-associated carcinogenesis in mice, reduce the colonic mucosal inflammation levels, and rebalance the fecal and mucosal intestinal microbiota.
